Lotel Gel contains Loteprednol etabonate 0.5% w/v, a corticosteroid indicated for the treatment of inflammatory conditions of the eye, including allergic conjunctivitis, postoperative inflammation, and anterior uveitis. Loteprednol etabonate is a corticosteroid designed to provide potent anti-inflammatory effects with a reduced risk of corticosteroid-related side effects due to its unique retrometabolic design, which allows rapid inactivation after exerting its therapeutic action. Lotel Gel is formulated as an ophthalmic gel to enhance ocular residence time, improve drug bioavailability, and provide sustained anti-inflammatory activity. It is typically administered topically to the affected eye(s) as directed by a healthcare professional, often multiple times daily depending on the severity of the condition. The use of Lotel Gel should be monitored carefully to avoid potential adverse effects such as increased intraocular pressure, cataract formation, or secondary infections. It is contraindicated in viral, fungal, or mycobacterial ocular infections. Patients should be advised to avoid contact lens use during treatment and to report any worsening symptoms promptly. Lotel Gel offers an effective therapeutic option for managing ocular inflammation with a favorable safety profile when used appropriately under medical supervision.